The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in the NCI60 cancer cell lines

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 3, 2014, Pages 530-541

  Sinnberg, Tobias ^a   Noor, Seema ^a   Venturelli, Sascha ^b   Berger, Alexander ^b   Schuler, Paul ^a   Garbe, Claus ^a   Busch, Christian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Ascorbate; Cancer; GLUT 1; HIF 1 ; Hypoxia; ROS; Therapy

Indexed keywords

ASCORBIC ACID; COBALT; COBALT CHLORIDE; CULTURE MEDIUM; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; PEROXIDE; REACTIVE OXYGEN METABOLITE;

CELL CYCLE G1 PHASE; CELL DEATH; CELL HYPOXIA; CELL PROLIFERATION; CHEMISTRY; CULTURE MEDIUM; DOSE RESPONSE; DRUG EFFECTS; HUMAN; IC50; INTRACELLULAR SPACE; METABOLISM; PARTIAL PRESSURE; TUMOR CELL LINE;

ASCORBIC ACID; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; COBALT; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; G1 PHASE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INHIBITORY CONCENTRATION 50; INTRACELLULAR SPACE; OXYGEN; PARTIAL PRESSURE; PEROXIDES; REACTIVE OXYGEN SPECIES;

EID: 84894593503     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12207     Document Type: Article

References (25)

1. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA. 1976; 73: 3685-9.
2. Padayatty SJ, Levine M. Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J Am Coll Nutr. 2000; 19: 423-5.
3. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA. 2005; 102: 13604-9.
4. Chen Q, Espey MG, Sun AY, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA. 2008; 105: 11105-9.
5. Du J, Martin SM, Levine M, et al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res. 2010; 16: 509-20.
6. Esme H, Cemek M, Sezer M, et al. High levels of oxidative stress in patients with advanced lung cancer. Respirology. 2008; 13: 112-6.
7. Chen Q, Espey MG, Sun AY, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA. 2007; 104: 8749-54.
8. Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med. 2009; 47: 32-40.
9. Schleich T, Rodemeister S, Venturelli S, et al. Decreased plasma ascorbate levels in stage IV melanoma patients. Metab Nutr Oncol. 2013: doi:10.1055/s-0033-1348256.
10. Hoffer LJ, Levine M, Assouline S, et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008; 19: 1969-74.
11. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003; 3: 276-85.
12. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009; 8: 579-91.
13. Michieli P. Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe? Cell Cycle. 2009; 8: 3291-6.
14. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2: 38-47.
15. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal. 2007; 9: 1221-35.
16. Moen I, Stuhr LE. Hyperbaric oxygen therapy and cancer-a review. Target Oncol. 2012; 7: 233-42.
17. Kuiper C, Molenaar IG, Dachs GU, et al. Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer Res. 2010; 70: 5749-58.
18. Rumsey SC, Kwon O, Xu GW, et al. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J Biol Chem. 1997; 272: 18982-9.
19. Welsh JL, Wagner BA, van't Erve TJ, et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013; 71: 765-75.
20. Chandel NS, Maltepe E, Goldwasser E, et al. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA. 1998; 95: 11715-20.
21. Roginsky VA, Stegmann HB. Ascorbyl radical as natural indicator of oxidative stress: quantitative regularities. Free Radic Biol Med. 1994; 17: 93-103.
22. Zouboulis CC, Garbe C, Krasagakis K, et al. A fluorometric rapid microassay to identify anti-proliferative compounds for human melanoma cells in vitro. Melanoma Res. 1991; 1: 91-5.
23. Browne G, Nesbitt H, Ming L, et al. Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance. Br J Cancer. 2012; 107: 1714-21.
24. Wan J, Chai H, Yu Z, et al. HIF-1alpha effects on angiogenic potential in human small cell lung carcinoma. J Exp Clin Cancer Res. 2011; 30: 77.
25. Ozerlat I. Kidney cancer: targeted therapy of glucose uptake via GLUT1 kills RCC cells. Nat Rev Urol. 2011; 8: 471.